Smith P, et al. – Analysts employed data on therapies purchased with prescription or over–the–counter (OTC) to ascertain the nature and extent of multiple–therapy used for rhinitis in Australia. Also, additional costs incurred by multiple–therapy use compared with intranasal corticosteroid (INCS) therapy alone, was explored. The significant burden posed on community pharmacy to address the needs of people with rhinitis symptoms was outlined. Results indicated, in light of the lack of evidence supporting a combination of INCS and oral antihistamines (OAH) therapy, the failure to translate the evidence that INCSs were the most effective monotherapy for moderate to severe and/or persistent rhinitis into clinical practice.